Article -> Article Details
| Title | Soft Tissue Sarcoma Market In-depth Survey and Trend Research Report 2017-2023 |
|---|---|
| Category | Fitness Health --> Men's Health |
| Meta Keywords | Soft Tissue Sarcoma Market |
| Owner | vinit |
| Description | |
| Tremains
the major driver of the global soft
tissue sarcoma market. Market Research Future (MRFR) reports that
the global soft tissue sarcoma market is set to grow at 8.2% CAGR during the
assessment period (2017-2023). Soft tissue
sarcoma is associated with various rare cancers, which includes clear cell
sarcoma, angiosarcoma, alveolar soft-part sarcoma, malignant mesenchymoma,
adult fibrosarcoma, clear cell sarcoma, rhabdomyosarcoma, and kaposi sarcoma.
Presently, there are limited treatment options available for soft tissue
sarcoma. However, the R&D pipelines are expected to grow in the forthcoming
years. In addition, increased focus on
pacing up approval process is likely to expand overall care and treatment
quality for soft tissue sarcoma in the years to come. Sunitinib (sutent),
doxorubicin (adriamycin), trabectedin (yondelis), bevacizumab (avastin), and
sirolimus (rapamune) are some of the pertinent drugs that are currently
available. Nevertheless, adverse side-effects of the treatment, high cost and
approval delays are some of the major market impediments. Global Soft Tissue Sarcoma Market: Segmental
Overview The
segmental analysis of the market has been conducted on the basis of disease
type, treatment, end-users and distribution channel. Based on disease type, the
market has been segmented into regional sarcoma, metastatic sarcoma, and local
sarcoma. On the basis of treatment type, the market has been segmented into
radiation therapy, anti-angiogenesis drugs, targeted therapy, and chemotherapy.
The radiation therapy segment is further sub-segmented into external radiation
therapy and internal radiation therapy. Based on end user, the market has been
segmented into long-term care centers, oncology centers and hospital. Based on
distribution channel, the market has been segmented into retail pharmacies,
hospital pharmacies and others. Global Soft Tissue Sarcoma Market: Regional
Segmentation The regions
covered in the report include the Middle East & Africa (MEA), Asia Pacific
(APAC), Europe and the Americas. In terms of revenue, the global soft tissue
sarcoma market is dominated by the Americas with North America being the
brighter market. This is mainly owing to the presence of an advanced healthcare
system in the region. Moreover, the rise in prevalence rate has also allowed
the market to climb faster in the region. The data released by American Cancer
Society, in 2016, approximately 12,390 people were suffering from soft tissue
sarcoma or related cancer. The market
is also witnessing a steady growth in Europe. Higher rate of incidence and
favourable reimbursement policies are some of factors that can be linked with
the market growth in the region. Asia Pacific
(APAC) accounts for the third spot in the global soft tissue sarcoma market in
terms of revenue. It is projected that the APAC soft tissue sarcoma market will
witness a strong growth over the next couple of years. Healthcare policy
reforms and increased efforts to improve healthcare services in countries such
as China, India, Taiwan among others. The Middle
East & Africa (MEA) market is also expected to exhibit a healthy growth
over the next couple of years. In MEA, much of the growth will be driven by the
strong investment in healthcare sector in GCC countries. Global Soft Tissue Sarcoma Market: Competitive
Landscape GlaxoSmithKline
plc (U.K), Pfizer, Inc. (U.S.), F. Hoffmann-La Roche AG (Genentech)
(Switzerland), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.),
Johnson & Johnson Services, Inc. (U.S.), Bristol-Myers Squibb (U.S.), and
Teva Pharmaceutical Industries Ltd (Israel) are among key company discussed in
the MRFR’s report. Industry News
| |